Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

In HIV-1-infected patients with extensive drug resistance, the optimization of background antiretroviral therapy is essential when changing drugs after treatment failure. The genotypic sensitivity ...

No, Atlanta is not experiencing an outbreak of HIV, although the rates of new diagnosis are considered high in some ...

Central Florida faces one of the highest HIV prevalence rates in the nation, with over 14,000 individuals currently living with the virus. Approximately 13% of those infected are unaware of their ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

JACKSON, Miss. (WLBT) -A new breakthrough drug for HIV Prevention has been approved by the FDA. The drug is called “Yeztugo” ...

More than 15% of individuals living with HIV and cancer have not received recommended first-line cancer therapy, according to results of a retrospective analysis.Among patients with HIV and cancer, ...

HIV, or human ... "This reconstitution system allows us to view just the pieces we want to investigate, without any other background noise from the complex environment of the cell," said ...